BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 34432216)

  • 1. Clinical Considerations of Isavuconazole Administration in High-Risk Hematological Patients: A Single-Center 5-Year Experience.
    Kronig I; Masouridi-Levrat S; Chalandon Y; Glampedakis E; Vernaz N; Van Delden C; Neofytos D
    Mycopathologia; 2021 Dec; 186(6):775-788. PubMed ID: 34432216
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and safety of isavuconazole compared with voriconazole as primary antifungal prophylaxis in allogeneic hematopoietic cell transplant recipients.
    Bogler Y; Stern A; Su Y; Lee YJ; Seo SK; Shaffer B; Perales MA; Papanicolaou GA; Neofytos D
    Med Mycol; 2021 Oct; 59(10):970-979. PubMed ID: 34036319
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A Single-Center, Open-Label Trial of Isavuconazole Prophylaxis against Invasive Fungal Infection in Patients Undergoing Allogeneic Hematopoietic Cell Transplantation.
    Stern A; Su Y; Lee YJ; Seo S; Shaffer B; Tamari R; Gyurkocza B; Barker J; Bogler Y; Giralt S; Perales MA; Papanicolaou GA
    Biol Blood Marrow Transplant; 2020 Jun; 26(6):1195-1202. PubMed ID: 32088367
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Isavuconazole shortens the QTc interval.
    Mellinghoff SC; Bassetti M; Dörfel D; Hagel S; Lehners N; Plis A; Schalk E; Vena A; Cornely OA
    Mycoses; 2018 Apr; 61(4):256-260. PubMed ID: 29178247
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Isavuconazole for the prophylaxis and treatment of invasive fungal disease: A single-center experience.
    Vu CA; Rana MM; Jacobs SE; Saunders-Hao P
    Transpl Infect Dis; 2021 Apr; 23(2):e13469. PubMed ID: 32946658
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Isavuconazole Is as Effective as and Better Tolerated Than Voriconazole for Antifungal Prophylaxis in Lung Transplant Recipients.
    Samanta P; Clancy CJ; Marini RV; Rivosecchi RM; McCreary EK; Shields RK; Falcione BA; Viehman A; Sacha L; Kwak EJ; Silveira FP; Sanchez PG; Morrell M; Clarke L; Nguyen MH
    Clin Infect Dis; 2021 Aug; 73(3):416-426. PubMed ID: 32463873
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Real-world use-Isavuconazole at a large academic medical center.
    Hassouna H; Athans V; Brizendine KD
    Mycoses; 2019 Jun; 62(6):534-541. PubMed ID: 30851214
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Isavuconazole Prophylaxis in Patients With Hematologic Malignancies and Hematopoietic Cell Transplant Recipients.
    Fontana L; Perlin DS; Zhao Y; Noble BN; Lewis JS; Strasfeld L; Hakki M
    Clin Infect Dis; 2020 Feb; 70(5):723-730. PubMed ID: 30958538
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Reasons for voriconazole prophylaxis discontinuation in allogeneic hematopoietic cell transplant recipients: A real-life paradigm.
    Chan SY; Hughes RM; Woo K; Perales MA; Neofytos D; Papanicolaou G
    Med Mycol; 2020 Nov; 58(8):1029-1036. PubMed ID: 32171012
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Isavuconazole versus voriconazole for primary treatment of invasive mould disease caused by Aspergillus and other filamentous fungi (SECURE): a phase 3, randomised-controlled, non-inferiority trial.
    Maertens JA; Raad II; Marr KA; Patterson TF; Kontoyiannis DP; Cornely OA; Bow EJ; Rahav G; Neofytos D; Aoun M; Baddley JW; Giladi M; Heinz WJ; Herbrecht R; Hope W; Karthaus M; Lee DG; Lortholary O; Morrison VA; Oren I; Selleslag D; Shoham S; Thompson GR; Lee M; Maher RM; Schmitt-Hoffmann AH; Zeiher B; Ullmann AJ
    Lancet; 2016 Feb; 387(10020):760-9. PubMed ID: 26684607
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety and pharmacokinetics of isavuconazole as antifungal prophylaxis in acute myeloid leukemia patients with neutropenia: results of a phase 2, dose escalation study.
    Cornely OA; Böhme A; Schmitt-Hoffmann A; Ullmann AJ
    Antimicrob Agents Chemother; 2015 Apr; 59(4):2078-85. PubMed ID: 25624327
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Isavuconazole for the Treatment of Invasive Mold Disease in Solid Organ Transplant Recipients: A Multicenter Study on Efficacy and Safety in Real-life Clinical Practice.
    Fernández-Ruiz M; Bodro M; Gutiérrez Martín I; Rodriguez-Álvarez R; Ruiz-Ruigómez M; Sabé N; López-Viñau T; Valerio M; Illaro A; Fortún J; Salto-Alejandre S; Cordero E; Fariñas MDC; Muñoz P; Vidal E; Carratalà J; Goikoetxea J; Ramos-Martínez A; Moreno A; Aguado JM;
    Transplantation; 2023 Mar; 107(3):762-773. PubMed ID: 36367924
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Isavuconazole to prevent invasive fungal infection in immunocompromised adults: Initial experience at an academic medical centre.
    Bowen CD; Tallman GB; Hakki M; Lewis Ⅱ JS
    Mycoses; 2019 Aug; 62(8):665-672. PubMed ID: 31050373
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Serial monitoring of isavuconazole blood levels during prolonged antifungal therapy.
    Furfaro E; Signori A; Di Grazia C; Dominietto A; Raiola AM; Aquino S; Ghiggi C; Ghiso A; Ungaro R; Angelucci E; Viscoli C; Mikulska M
    J Antimicrob Chemother; 2019 Aug; 74(8):2341-2346. PubMed ID: 31119272
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of isavuconazole on tacrolimus and sirolimus serum concentrations in allogeneic hematopoietic stem cell transplant patients: A drug-drug interaction study.
    Kieu V; Jhangiani K; Dadwal S; Nakamura R; Pon D
    Transpl Infect Dis; 2019 Feb; 21(1):e13007. PubMed ID: 30295407
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A Case Series and Literature Review of Isavuconazole Use in Pediatric Patients with Hemato-oncologic Diseases and Hematopoietic Stem Cell Transplantation.
    Decembrino N; Perruccio K; Zecca M; Colombini A; Calore E; Muggeo P; Soncini E; Comelli A; Molinaro M; Goffredo BM; De Gregori S; Giardini I; Scudeller L; Cesaro S
    Antimicrob Agents Chemother; 2020 Feb; 64(3):. PubMed ID: 31871077
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical and Pharmacological Considerations for Concomitant Administration of Posaconazole and Isavuconazole with Letermovir.
    Terrier J; Zanella MC; Masouridi-Levrat S; Kronig I; Chalandon Y; Vernaz N; Van Delden C; Papanicolaou G; Neofytos D
    Antimicrob Agents Chemother; 2021 May; 65(6):. PubMed ID: 33782007
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Isavuconazole for treatment of rare invasive fungal diseases.
    Cornely OA; Mullane KM; Ostrosky-Zeichner L; Maher RM; Croos-Dabrera R; Lu Q; Lademacher C; Perfect JR; Oren I; Schmitt-Hoffmann AH; Giladi M; Marty FM; Rahav G
    Mycoses; 2018 Aug; 61(8):518-533. PubMed ID: 29611246
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Isavuconazole for treatment of invasive fungal diseases caused by more than one fungal species.
    Marty FM; Cornely OA; Mullane KM; Ostrosky-Zeichner L; Maher RM; Croos-Dabrera R; Lu Q; Lademacher C; Oren I; Schmitt-Hoffmann AH; Giladi M; Rahav G; Perfect JR
    Mycoses; 2018 Jul; 61(7):485-497. PubMed ID: 29611227
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and safety of Isavuconazole for the treatment of invasive
    Sivasubramanian G; Chandrasekar PH
    Expert Opin Pharmacother; 2022 Apr; 23(5):543-549. PubMed ID: 35099351
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.